The international, multicenter, prospective study will include 100 patients in the U.S. and Europe. Today’s news was reported at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery in National Harbor, Md.

Ali Azizzadeh, M.D., FACS, professor and chief of division of Vascular and Endovascular Surgery in the department of Cardiothoracic and Vascular Surgery at McGovern Medical School at UTHealth, is the U.S. principal investigator for the trial and performed the first procedure on a patient with a descending TAA.

Dr. Azizzadeh reports the first patient treated in the investigational device exemption (IDE) trial is an 88-year-old male who is doing well post-treatment.

"The Valiant Evo clinical study has the potential to expand the applicability of thoracic endovascular aortic repair (TEVAR) to a wider spectrum of patients," said Dr. Azizzadeh.

The Valiant Evo system is a lower profile evolution of the market-leading Valiant Captivia(TM)system, which has treated more than 85,000 patients globally. The Valiant Evo system is designed to deliver a minimally invasive treatment option to a greater number of patients with an 18F and 20F outer diameter profile for most size configurations, proximal closed web and FreeFlo configurations with tip capture, and high stent graft conformability.

Additional features include broader tapered offerings and longer lengths for anatomical customization, in addition to an improved ergonomic delivery system.

In the United States, the Valiant Evo is an investigational device and not yet approved for commercial use.

"Medtronic is committed to developing meaningful innovation to deliver better patient outcomes. With the Valiant Evo system, we are leveraging a decade of clinical experience and physician collaboration with the Valiant system, with a lower profile device that may help to treat more complex aortic disease," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic.

"By listening to physicians we believe that this innovation may support greater access to less invasive treatment options for more patients globally."

Approximately six out of 100,000 people globally experience a TAA, a blood-filled bulge or ballooning of the aorta that runs through the chest and can lead to a life-threatening rupture and hemorrhage if not treated. Most people with TAA do not have any symptoms; however, risk factors include smoking, obesity, heredity, injury, or other disease.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.